13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
77 檔
32.0%
The Q4 2025 SEC filing reveals that DAFNA Capital Management LLC held a total portfolio value of $524.4M, covering 77 public equity positions.
DAFNA Capital Management LLC executed strategic sector rebalancing during Q4 2025, establishing 12 new positions while fully exiting 10 holdings and trimming 29 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 11.18% | +7.24% | -8.01% | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.53% | -3.32% | -16.19% | |
| 3 | STXS | Stereotaxis Inc | Stock-Other | 7.31% | -1.24% | — | |
| 4 | ATRC | Atricure Inc | Stock-Other | 5.49% | -0.69% | +0.87% | |
| 5 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.48% | -0.47% | -6.06% | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 4.07% | -0.08% | -6.15% | |
| 7 | AXGN | Axogen Inc | Stock-Other | 3.63% | -0.04% | -35.76% | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.00% | -0.43% | — | |
| 9 | IBB | Ishares Biotechnology ETF | ETF-Tech | 2.67% | -0.85% | -33.57% | |
| 10 | BHVN | Biohaven Ltd. | Stock-Other | 2.51% | -1.24% | +306.08% | |
| 11 | RCUS | Arcus Biosciences Inc | Stock-Other | 2.39% | +0.42% | -31.28% | |
| 12 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.33% | -0.26% | — | |
| 13 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.16% | -4.77% | EXIT | |
| 14 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.81% | -0.53% | — | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 1.40% | -1.21% | EXIT | |
| 16 | DXCM | Dexcom Inc | Stock-Healthcare | 1.36% | -0.12% | +34.67% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.36% | +0.24% | -44.51% | |
| 18 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.34% | -1.22% | EXIT | |
| 19 | CMPS | Compass Pathways PLC | Stock-Other | 1.30% | +2.39% | — | |
| 20 | INGN | Inogen Inc | Stock-Other | 1.29% | -0.15% | +36.56% | |
| 21 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.27% | -1.35% | EXIT | |
| 22 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.22% | +2.23% | +89.02% | |
| 23 | MBX | Mbx Biosciences Inc | Stock-Other | 1.21% | -1.07% | +94.43% | |
| 24 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.02% | -0.30% | -17.48% | |
| 25 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.99% | -0.15% | — | |
| 26 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.93% | — | -4.69% | |
| 27 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.92% | +0.96% | -25.26% | |
| 28 | IMVT | Immunovant Inc | Stock-Other | 0.89% | +0.25% | -21.39% | |
| 29 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.88% | -0.16% | — | |
| 30 | HELP | Cybin Inc | Stock-Other | 0.86% | +0.11% | — | |
| 31 | ALKS | Alkermes plc | Stock-Healthcare | 0.85% | -0.11% | -3.34% | |
| 32 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.83% | -0.91% | -8.62% | |
| 33 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.80% | -0.15% | -35.88% | |
| 34 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.79% | -0.16% | -4.81% | |
| 35 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.76% | -0.17% | +91.64% | |
| 36 | NKTR | Nektar Therapeutics | Stock-Other | 0.74% | +1.54% | +36.37% | |
| 37 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.74% | -0.04% | — | |
| 38 | IPSC | Century Therapeutics Inc | Stock-Other | 0.65% | -0.13% | +63.92% | |
| 39 | ✓ | Immatics NV | Stock-Other | 0.64% | -0.28% | +11.12% | |
| 40 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.60% | -0.03% | -37.29% | |
| 41 | MPLT | Maplight Therapeutics Inc | Stock-Other | 0.59% | +0.38% | — | |
| 42 | ALGN | Align Technology Inc | Stock-Healthcare | 0.58% | -0.13% | +45.45% | |
| 43 | KURA | Kura Oncology Inc | Stock-Other | 0.57% | -0.19% | -49.10% | |
| 44 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.56% | +0.16% | -26.66% | |
| 45 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.53% | +0.07% | — | |
| 46 | PROF | Profound Medical CORP | Stock-Other | 0.52% | -0.06% | — | |
| 47 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.51% | — | +35.28% | |
| 48 | ✓ | Mediwound LTD | Stock-Other | 0.49% | -0.09% | — | |
| 49 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.49% | — | -7.75% | |
| 50 | PODD | Insulet CORP | Stock-Healthcare | 0.45% | +1.28% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | +3.6% | -8.01% | Trim |
| 2 | BHVN | Biohaven Ltd. | +1.6% | +306.08% | Add |
| 3 | MBX | Mbx Biosciences Inc | +0.8% | +94.43% | Add |
| 4 | TNDM | Tandem Diabetes Care Inc | +0.7% | — | Unchanged |
| 5 | DNLI | Denali Therapeutics Inc | +0.6% | +89.02% | Add |
| 6 | IDYA | Ideaya Biosciences Inc | +0.4% | -6.15% | Trim |
| 7 | IPSC | Century Therapeutics Inc | +0.4% | +63.92% | Add |
| 8 | DAWNGBX | Day One Biopharmaceuticals I | +0.4% | — | Unchanged |
| 9 | AXGN | Axogen Inc | +0.4% | -35.76% | Trim |
| 10 | CATBUSD | Astria Therapeutics Inc | +0.4% | -4.69% | Trim |
| 11 | BCRX | Biocryst Pharmaceuticals Inc | +0.4% | +91.64% | Add |
| 12 | ATRC | Atricure Inc | +0.3% | +0.87% | Add |
| 13 | RCUS | Arcus Biosciences Inc | +0.3% | -31.28% | Trim |
| 14 | DXCM | Dexcom Inc | +0.3% | +34.67% | Add |
| 15 | CLDX | Celldex Therapeutics Inc | +0.3% | +179.46% | Add |
| 16 | ALGN | Align Technology Inc | +0.2% | +45.45% | Add |
| 17 | LXEO | Lexeo Therapeutics Inc | +0.2% | -4.81% | Trim |
| 18 | GPCR | Structure Therapeutics Inc | +0.2% | -37.29% | Trim |
| 19 | SPRY | Ars Pharmaceuticals Inc | +0.2% | +35.28% | Add |
| 20 | CMPS | Compass Pathways PLC | +0.2% | — | Unchanged |
| 21 | ✓ | Immatics NV | +0.2% | +11.12% | Add |
| 22 | XENE | Xenon Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 23 | IMVT | Immunovant Inc | +0.1% | -21.39% | Trim |
| 24 | CYTK | Cytokinetics Inc | +0.1% | -6.06% | Trim |
| 25 | 4XC1 | Kalvista Pharmaceuticals Inc | +0.1% | -15.60% | Trim |
| 26 | INGN | Inogen Inc | +0.1% | +36.56% | Add |
| 27 | VKTX | Viking Therapeutics Inc | +0.1% | -7.75% | Trim |
| 28 | EWTX | Edgewise Therapeutics Inc | +0.1% | -25.26% | Trim |
| 29 | ✓ | Polypid LTD | 0% | — | Unchanged |
| 30 | ERAS | Erasca Inc | 0% | -27.30% | Trim |
| 31 | ALLO | Allogene Therapeutics Inc | 0% | — | Unchanged |
| 32 | LRMR | Larimar Therapeutics Inc | 0% | -8.62% | Trim |
| 33 | FHTX | Foghorn Therapeutics Inc | 0% | — | Unchanged |
| 34 | AUTL | Autolus Therapeutics PLC | 0% | — | Unchanged |
| 35 | NGNE | Neurogene Inc | — | -7.90% | Trim |
| 36 | ✓ | Compugen LTD | — | — | Unchanged |
| 37 | BCYC | Bicycle Therapeutics Plc-adr | 0% | — | Unchanged |
| 38 | ✓ | Mediwound LTD | 0% | — | Unchanged |
| 39 | RAPP | Rapport Therapeutics Inc | 0% | — | Unchanged |
| 40 | BNTX | Biontech Se-adr | 0% | — | Unchanged |
| 41 | NKTR | Nektar Therapeutics | 0% | +36.37% | Add |
| 42 | ORIC | Oric Pharmaceuticals Inc | 0% | +34.75% | Add |
| 43 | ✓ | Adc Therapeutics SA | -0.1% | -36.86% | Trim |
| 44 | PODD | Insulet CORP | -0.1% | — | Unchanged |
| 45 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | -0.1% | — | Unchanged |
| 46 | ✓ | Proqr Therapeutics N.v. | -0.1% | — | Unchanged |
| 47 | OBIO | Orchestra Biomed Holdings In | -0.1% | -65.12% | Trim |
| 48 | LKFT | Lakefront Biotherapeutic-adr | -0.1% | — | Unchanged |
| 49 | NBIX | Neurocrine Biosciences Inc | -0.1% | — | Unchanged |
| 50 | TELA | Tela Bio Inc | -0.1% | — | Unchanged |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 77 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RVMD, XBI, STXS) accounted for 32.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
PRCT
市值: $3.8M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $20.8M
During Q4 2025, DAFNA Capital Management LLC's top holdings by market value included RVMD (11.2%)、XBI (9.5%)、STXS (7.3%). The largest single position, RVMD, represented 11.2% of total portfolio value.
In Q4 2025, DAFNA Capital Management LLC made 67 total portfolio adjustments, initiating 12 new buys, adding to 16 positions, trimming 29 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.